HCPLive

Ana Molina, MD, of MSKCC Shares Important Information on Kidney Cancer

$shareThis$

Most Popular

Recommended Reading

For patients with chronic lymphocytic leukemia, the Bruton tyrosine kinase inhibitor ibrutinib is effective, and prognosis is poor after discontinuation, according to a study published online Feb. 26 in JAMA Oncology. The research identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation.
Patients with metastatic colorectal cancer that started on the left side may be more likely to survive than those whose disease originated on the right side, according to research published in the March issue of the Journal of the National Cancer Institute.
The US Food and Drug Administration (FDA) approved a new antibacterial drug combination product, ceftazidime-avibactam (Avycaz/Forest Labs), for use in complicated intra-abdominal infections.
US recommendations against the prostate-specific antigen test for prostate cancer might have prompted a small but measurable increase in the number of higher-risk cases diagnosed recently, according to a new study. Findings from the study are to be presented Thursday at the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, held from Feb. 26 to 28 in Orlando, Fla.
$vacMongoViewPlus$ $vAR$